Indication

Squamous cell carcinoma of skin

Squamous cell carcinoma of the skin is a malignant non-melanoma cutaneous neoplasm arising from epidermal keratinocytes. Read more about Squamous cell carcinoma of skin

5 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Squamous cell carcinoma of skin therapies.

Showing 1–5 of 5 drugs

LIBTAYO (cemiplimab-rwlc)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·BASAL CELL CARCINOMA OF SKIN·+3
Regeneron Pharmaceuticals, Inc.
Sponsored

KEYTRUDA (pembrolizumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme

UNLOXCYT (cosibelimab-ipdl)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·SQUAMOUS CELL CARCINOMA OF SKIN
SUN PHARMACEUTI
Filter & compare in the drug finder →Opens the drug finder with Squamous cell carcinoma of skin preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Squamous cell carcinoma of skin.

Squamous cell carcinoma of the skin is a malignant non-melanoma cutaneous neoplasm arising from epidermal keratinocytes.

It primarily affects the integumentary system, most commonly emerging in older adults, fair-skinned individuals, and immunocompromised populations on chronically sun-exposed anatomical sites such as the head, neck, and extremities.

Pathophysiologically driven by cumulative ultraviolet radiation that induces somatic mutations—notably within the *TP53* tumor suppressor gene—the malignancy is characterized by atypical keratinocyte proliferation with dermal invasion.

Clinically, it typically manifests as an indurated, hyperkeratotic papule, scaly plaque, or ulcerated nodule with potential for destructive local extension and regional lymph node metastasis.

Personalize your experience

Follow Squamous cell carcinoma of skin and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it